Quarterly corporate earnings, Chinese growth, UK wages - what's moving markets

United Continental (UAL) PT Raised to $80 at Citi

Citi analyst Stephen Trent raised the price target on United Continental (NASDAQ: UAL) to $80.00 (from $73.00) while maintaining a Buy rating.

The analyst comments "Forecast adjustments for Buy-rated United Airlines include the incorporation of stronger, expected revenue per available seat mile or RASM,... More

Wells Fargo on Bank of America (BAC): 'A turn in NII should lead to positive operating leverage...'

Wells Fargo analyst Mike Mayo reiterated an Overweight rating and $44.00 price target on Bank of America (NYSE: BAC).

The analyst comments "Headwinds now closer to tailwinds. BAC now expects NII (which beat) to inflect post 2Q24 given deposit pressure easing, better... More

Morgan Stanley (MS) PT Raised to $109 at Jefferies

Jefferies analyst Daniel Fannon raised the price target on Morgan Stanley (NYSE: MS) to $109.00 (from $107.00) while maintaining a Buy rating.

The analyst comments "Post 1Q24 results, we increase our EPS est's for 2Q24/2024 to $1.74/$7.25 from $1.59/$6.50 previously. Positive revisions reflect continued strength in IB... More

Bank of America (BAC) PT Raised to $37 at BMO Capital

BMO Capital analyst James Fotheringham raised the price target on Bank of America (NYSE: BAC) to $37.00 (from $36.00) while maintaining a Market Perform rating.

The analyst comments "Following BAC's 1Q24 top-line beat, we raise estimates by +3%; higher than previously modeled non-interest income (ECM, advisory,... More

UnitedHealth Group (UNH) PT Lowered to $555 at RBC Capital

RBC Capital analyst Ben Hendrix lowered the price target on UnitedHealth Group (NYSE: UNH) to $555.00 (from $596.00) while maintaining a Outperform rating.

The analyst comments "While we are pleased to see some recovery in UNH shares on a betterthan-feared first quarter print and... More

Johnson & Johnson (JNJ) PT Lowered to $175 at RBC Capital

RBC Capital analyst Shagun Singh lowered the price target on Johnson & Johnson (NYSE: JNJ) to $175.00 (from $181.00) while maintaining a Outperform rating.

The analyst comments "JNJ's stock traded modestly lower post-Q1'24, where it delivered inline sales and EPS beat. JNJ tightened FY24 operational guidance... More

UnitedHealth Group (UNH) PT Raised to $571 at Piper Sandler

Piper Sandler analyst Jessica Tassan raised the price target on UnitedHealth Group (NYSE: UNH) to $571.00 (from $566.00) while maintaining a Overweight rating.

The analyst comments "After a challenging CY23, UHC enters CY24 with restrained growth, balanced benefit design, deliberate care delivery and... More

Johnson & Johnson (JNJ) PT Lowered to $170 at BofA Securities

BofA Securities analyst Geoff Meacham lowered the price target on Johnson & Johnson (NYSE: JNJ) to $170.00 (from $180.00) while maintaining a Neutral rating.

The analyst comments "JNJ shares traded down today (-2.0%; DRG -0.3%) despite a solid 1Q and reported guidance midpoint unchanged, which we suspect was due to disappointing Carvykti sales (-1% q/q) and Vision business (-3% y/y).... More

Morgan Stanley (MS) PT Raised to $108 at CFRA

CFRA analyst Ken Leon raised the price target on Morgan Stanley (NYSE: MS) to $108.00 (from $97.00) while maintaining a Buy rating.

The analyst comments "
MS stands to significantly benefit from the early stage recovery in investment banking and asset management. We... More

Morgan Stanley (MS) earnings beat lifts stock

Morgan Stanley (NYSE: MS) has reported a notable increase in its first-quarter earnings and revenue, surpassing analyst expectations and prompting a 2% rise in its shares premarket. The financial services firm announced net revenues of $15.1 billion for the quarter ended March 31, 2024, a 4.1% increase from the $14.5 billion reported in the same period last year. Adjusted earnings per share (EPS) reached $2.02, exceeding the analyst estimate of $1.67 by $0.35.

Chief... More

Johnson & Johnson (JNJ) posts mixed results, narrows full-year guidance

Johnson & Johnson (NYSE: JNJ) reported mixed financial results for the first quarter of 2024, with adjusted earnings per share (EPS) slightly surpassing analyst expectations, while revenue fell marginally short of estimates. The healthcare giant posted an adjusted EPS of $2.71, which was $0.07 higher than the consensus estimate of $2.64. However, quarterly revenue was a hair's breadth away from consensus, coming in at $21.38 billion against... More

Goldman Sachs (GS) PT Raised to $405 at RBC Capital

RBC Capital analyst Gerard Cassidy raised the price target on Goldman Sachs (NYSE: GS) to $405.00 (from $390.00) while maintaining a Sector Perform rating.

The analyst comments "GS is a preeminent global investment bank with a leading position in the global markets, which... More

Goldman Sachs (GS) PT Raised to $360 at BMO Capital

BMO Capital analyst James Fotheringham raised the price target on Goldman Sachs (NYSE: GS) to $360.00 (from $349.00) while maintaining a Market Perform rating.

The analyst comments "Following GS's 1Q24 big GB&M-driven beat, we raise out-year estimates by as much as +3%; higher-than-previously modeled... More